retatrutide clinical trials sign up New Phase 3 data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats A New Obesity Drug Delivered

The Alliance for Pharmacy Compounding (the compounding industry's own trade group) has told its members twice: do not compound retatrutide

While the data are still preliminary, McCoy says, they indicate that retatrutide has greater efficacy over a placebo for blood sugar and weight loss compared with previous trials of tirzepatide (which targets two receptors) and semaglutide

If you can, get bloodwork done (blood sugar and cholesterol levels)

Explore peptide profiles, dosage calculators, and research tools at PeptidesExplorer

As of March 2026, it is still an experimental drug being tested in clinical trials run by Eli Lilly